KALA BIO, Inc. (KALA)
(Real Time Quote from BATS)
$5.60 USD
+0.20 (3.70%)
Updated Jun 21, 2024 11:50 AM ET
4-Sell of 5 4
F Value B Growth C Momentum D VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 321 - 340 ( 366 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
INVELTYS Launched With Specialty Sales Organization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
FDA Accepts KPI-121 0.25% NDA for Dry Eye Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Dry Eye Regulatory Timing May Create Potential Buying Opportunity in H2:19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Cash Runway through Key Catalysts; Next: INVELTYS - Launch in Early 2019
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
3Q18 Financial Results Reported; Reiterate Buy and Reduce Price Target to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
KPI-121 0.25% NDA Submitted for Dry Eye Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
NDA Submitted for KPI-121 0.25% in Dry Eye Disease
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Financing Covers Important Milestones from YE:18 Into 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Financing Completed; Reiterate Buy and Lowering Price Target to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Unclassified
INVELTYS Still the First and Only Twice-Daily Postoperative Ocular Corticosteroid; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: KALA BIO, Inc.
Industry: Unclassified
FDA Approves INVELTYS for Post-Surgery Eye Pain; U.S. Launch in Q1:19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Unclassified
FDA Approves INVELTYS; Commercial Launch in Early 2019; Reiterate Buy and Raising Target to $37
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Unclassified
Company: KALA BIO, Inc.
Industry: Unclassified
Cequa Approval Should Not Affect Short-Term DED Treatment Market; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Unclassified
HEALTHCARE - 2018 Wedbush PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: KALA BIO, Inc.
Industry: Unclassified
Company: KALA BIO, Inc.
Industry: Unclassified
2Q18 Results Reported; INVELTYS PDUFA Decision Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Unclassified
Q2 Financials; We Anticipate INVELTYS Approval by August 24 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L